The PPD skin test is a method used to diagnose silent (latent) tuberculosis (TB) infection. PPD stands for purified protein derivative.
Purified protein derivative standard; TB skin test; Tuberculin skin test; Mantoux test
You will need 2 visits to your doctor's office for this test.
At the first visit, the health care provider will clean an area of your skin, usually the inside of your forearm. You will get a small shot (injection) that contains PPD. The needle is gently placed under the top layer of skin, causing a bump (welt) to form. This bump usually goes away in a few hours as the material is absorbed.
After 48 to 72 hours, you must return to your provider's office. Your provider will check the area to see if you have had a strong reaction to the test.
There is no special preparation for this test.
Tell your provider if you have ever had a positive PPD skin test. If so, you should not have a repeat PPD test, except under unusual circumstances.
Tell your provider if you have a medical condition or if you take certain medicines, such as steroids, which can affect your immune system. These situations may lead to inaccurate test results.
Tell your provider if you have received the BCG vaccine and if so, when you received it. (This vaccine is only given outside of the United States).
You will feel a brief sting as the needle is inserted just below the skin surface.
This test is done to find out if you have ever come in contact with the bacteria that causes TB.
TB is an easily spread (contagious) disease. It most often affects the lungs. The bacteria can remain inactive (dormant) in the lungs for many years. This situation is called latent TB.
Most people in the United States who are infected with the bacteria do not have signs or symptoms of active TB.
You are most likely to need this test if you:
A negative reaction usually means you have never been infected with the bacteria that cause TB.
With a negative reaction, the skin where you received the PPD test is not swollen, or the swelling is very small. This measurement is different for children, people with HIV, and other high-risk groups.
The PPD skin test is not a perfect screening test. A few people infected with the bacteria that cause TB may not have a reaction. Also, diseases or medicines that weaken the immune system may cause a false-negative result.
An abnormal (positive) result means you have been infected with the bacteria that cause TB. You may need treatment to lower the risk of the disease coming back (reactivation of the disease). A positive skin test does not mean that a person has active TB. More tests must be done to check whether there is active disease.
A small reaction (5 mm of firm swelling at the site) is considered to be positive in people:
Larger reactions (larger than or equal to 10 mm) are considered positive in:
In people with no known risks of TB, 15 mm or more of firm swelling at the site indicates a positive reaction.
People who were born outside the United States who have had a vaccine called BCG may have a false-positive test result.
There is a very small risk of severe redness and swelling of the arm in people who have had a previous positive PPD test and who have the test again. This reaction can also occur in a few people who have not been tested before.
Chernecky CC, Berger BJ. Mantoux skin test (PPD test, purified protein derivative test, Tb test, tuberculin skin test, TST, tuberculosis test) - diagnostic. In: Chernecky CC, Berger BJ, eds. Laboratory Tests and Diagnostic Procedures. 6th ed. Philadelphia, PA: Elsevier Saunders; 2013:764-5.
Fitzgerald DW, Sterling TR, Haas DW. Mycobacterium tuberculosis. In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 8th ed. Philadelphia, PA: Elsevier Saunders; 2015:chap 251.
Reviewed By: Jatin M. Vyas, MD, PhD, Assistant Professor in Medicine, Harvard Medical School; Assistant in Medicine, Division of Infectious Disease, Department of Medicine, Massachusetts General Hospital, Boston, MA. Also reviewed by David Zieve, MD, MHA, Isla Ogilvie, PhD, and the A.D.A.M. Editorial team.